Overview

Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
Imprimis Pharmaceuticals is investigating a proprietary, topical cream formulation consisting of 10% ketoprofen (containing 100 mg of ketoprofen in 1gram of cream) for the local treatment of acute musculoskeletal pain.
Phase:
Phase 3
Details
Lead Sponsor:
Imprimis Pharmaceuticals, Inc.
Collaborator:
Cato Research
Treatments:
Ketoprofen